Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32…

By D. Krag, S. Anderson, T. Julian, Ann M. Brown, S. Harlow, J. Costantino, T. Ashikaga, D. Weaver, E. Mamounas, L. Jalovec and 5 more. The Lancet Oncology, 2010

1,642 citations recorded by the source corpus.

Subfields: Cancer Research, Pathology and Forensic Medicine, Surgery

View Paper: https://www.semanticscholar.org/paper/b337f62cc943bdbfce9f81d35ad61f79da2a7549

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

E. Senkus
A. Goldhirsch
S. Kyriakides
S. Ohno
W. Wood
F. Penault-Llorca
A. Coates
F. Cardoso

Citations in the corpus

Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update. (2014, background): “In four of those five trials, survival outcomes were the primary end points.(3,6,9,13) Of these four trials, NSABP B32 had the largest number of participants (N 3,989).”
American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline (2016, neutral): “lymphedema is much lower with sentinel lymph node dissections than with the full axillary lymph node dissection previously performed in all cases.(59) Lymphedema may occur immediately after treatment or develop after many years.”
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2015, background): “With appropriate training in the technique, acceptably low false-negative rates and favorable axillary recurrence rates following SLNB are achievable [55].”
Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. (2015, background): “8%.(2) The use of SNB after neoadjuvant chemotherapy (NAC) has been the subject of some controversy.”
Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 (2011, result): “New results from clinical trials supported the safety of omitting axillary dissection not only in patients with a negative sentinel node biopsy [19] but also in patients with a clinically nodenegative axilla but pathological macrometastatic involvement of one or two sentinel nodes in the context of ”